Objectives: From April 2012, UK centres will be funded based on treatment patients needed the 12 months leading up to annual review the previous calendar year. Thus, funding will be based on data 3−15 months old, potentially underestimating patients' health needs. We investigated whether data from the previous calendar year (only 3 months old) were better at predicting subsequent treatment needs.
Background: Intravenous (IV) antibiotic (ABX) treatments for CF pulmonary exacerbations (PEx) are associated with poor lung function. We studied how changes in CF pulmonary health have affected PEx treatment incidence. Methods: IV and oral/inhaled (nonIV) ABX PEx treatment incidence from 1995-2005 stratified by age group (<6, 6−12, 13−17, 18 yr) was calculated from the Epidemiologic Study of CF. Modified sign/symptom scores (range 0−4) associated with PEx treatment [Rabin et al., Ped. Pulm. 2004; 37: 400] were calculated. Results: 213,054 PEx ABX treatments occurred over 185,981 patient years (pt-yr) studied. ABX treatment (Tx) incidence fell 0.07/yr (R 2 = 0.85; P < 0.001) from 1.68 Tx/pt-yr in the 18 yr group and 0.04/yr (R 2 = 0.74; P < 0.001) in the 13−17 yr group, while rising 0.03/yr from 0.55 Tx/pt-yr (R 2 = 0.63; P = 0.004) in the <6 yr group, the latter due to a 0.04/yr (R 2 = 0.64; P = 0.001) nonIV ABX treatment increase. Tx incidence was unchanged in the 6−12 yr group. 30,337 PEx were evaluable for Rabin clinical score. Mean clinical scores at nonIV ABX treatment dropped 0.01-0.02 units/yr (R 2 range 0.34-0.77; P < 0.001 to P = 0.06); IV ABX treatment score changes showed no pattern by age, with <6 yr group mean scores dropping 0.03 units/yr (R 2 = 0.45; P = 0.02). Conclusions: PEx ABX treatment incidence changed significantly from 1995-2005, with children receiving more ABX treatments and adults receiving fewer. Clinical thresholds for intervention declined over the 11-year study period for nonIV ABX treatment in all age groups, and for IV ABX treatment in patients aged <6. These data underscore the importance of including nonIV ABX treatments and treatment thresholds in PEx analyses. Discussion: A significant increase in NFEV 1 patients was seen over an 11-year period, with a significant increase in adults. This could be explained by the significant increase in NFEV 1 patients with atypical CF. A more detailed genetic analysis of CFTR over 11 years explains the increase in patients with two known CFTR mutations. Separate analysis of the F508del/F508del adults is needed to conclude that improved CF care over 11 years had also its impact on the increased proportion of NFEV 1 CF patients.
